TickerTalks
Browse all tickers →
TickerTalks›$WGS
WGWGS

GeneDx Holdings Corp.

$WGS·$2.6B·Medical - Diagnostics & Research·Healthcare
$85.93-2.8%YTD-34.6%1Y-24.6%
Price updated 9h ago·X counts updated 1d ago
WGWGS
$WGSGeneDx Holdings Corp.
$85.93-2.79%31 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $WGS on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

31X posts · last 7 days
Sep 11Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $WGS's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-28

GeneDx posts are bullish following diagnostics thesis playing out (WGS/CAI/TEM/XGN benefiting from AI). Bulls cite WGS as one of the strongest DX stocks with strong Friday finish alongside MP/FIGR/CAI/ALM. Sample small; tone dominates bullish.

Read what X is saying about $WGS

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $WGS — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Comeback attemptWinding up for a moveAI verdict · as of 2026-09-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

GeneDx just launched NPC GenomeComplete with Beren Therapeutics — a whole-exome genomics leader down 35% YTD as CEO Stueland sold $1M mid-September.

GeneDx Holdings is a genomic-testing franchise (pediatric and rare-disease whole exome/genome sequencing, AI clinical reporting) — a business through a rough YTD but with real product-line momentum and the emerging Tempus WGS competition. The stock is down 22% over 12 months.

  • Q2 delivered a beat: EPS $0.01 vs -$0.19 estimate (+105% surprise), revenue $114M — meaningful operational improvement, though prior quarters have been volatile (-367% surprise in Q1).
  • The Sept 9 Beren Therapeutics NPC GenomeComplete launch (Niemann-Pick Disease Type C diagnostics) is the specific commercial catalyst — real product-line expansion into rare-disease targeting.
  • Insider signal is heavily distributive: CEO Katherine Stueland sold $1M+ across Sept 9-16, CFO Feeley sold $500K+ in same window — coordinated cluster of officer distribution offsetting the operational momentum, though the Sept 11 Tempus WGS dataset launch adds competitive pressure.

Q3 earnings on Oct 27 is the confirmation — a beat plus firm NPC GenomeComplete and Tempus-competitive commentary extends the story; another quarter of margin volatility or a Tempus-competitive market-share flag and the tape stays coiled.

Agrees with X sentimentX bulls correctly frame WGS as one of the strongest DX stocks alongside CAI/TEM/XGN benefiting from the AI-diagnostics thesis and a strong Friday finish. Sample is small but the framing aligns with the Beren launch and the Q2 beat. Partial agreement — the insider distribution is a real caveat.

What to watch: Q3 earnings on Oct 27 — a beat plus firm NPC GenomeComplete and Tempus-competitive commentary extends the story; another quarter of margin volatility or a Tempus-competitive market-share flag and the tape stays coiled.

On the calendar: 2026-10-27 — Q3 earnings

npc genome launchtempus wgs competitioncluster officer selling

Read the AI verdict on $WGS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Genomic testing company using AI to interpret whole exome and genome sequencing for rare disease diagnosis.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $WGS.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $WGS

Partial — Genomic testing company using AI to interpret whole exome and genome sequencing for rare disease diagnosis.

Industry benchmark

18-name peer basket
+50.2%YTD
+85.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-23.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-8.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-7.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-27.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
68.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 3, 2026$0.01$-0.19+105.3%
Q1 2026May 4, 2026$-0.28$-0.06-366.7%
Q4 2025Feb 23, 2026$0.14$0.11+27.3%
Q3 2025Oct 28, 2025$0.49$0.28+75.0%
Next earningsTue, Oct 27·consensus EPS $0.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$102.3M+17.4%66.7%-25.6%$-2.16$-38.9M
Q4 FY25$121.0M+26.5%65.2%-11.3%$-0.61$-7.4M
Q3 FY25$116.7M+51.9%72.4%-2.8%$-0.27$9.6M
Q2 FY25$102.7M+45.6%69.0%8.7%$0.38$8.1M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$481.9M$467.4M – $497.7M$0.10$0.10 – $0.107
FY27$598.5M$580.5M – $618.1M$1.17$1.12 – $1.226
FY28$749.2M$683.6M – $819.1M$1.84-$3.23 – $6.906
FY29$865.1M$839.0M – $893.3M$3.02$2.90 – $3.154
FY30$1.1B$1.0B – $1.1B$5.11$4.90 – $5.323

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.39%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+6.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 27.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.015-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 16Katherine StuelandCEO10.5K sh$1.0MSellSep 16Kevin FeeleyCFO3.7K sh$364KSellSep 9Katherine StuelandCEO3.7K sh$311KSellSep 9Kevin FeeleyCFO1.3K sh$108KSellSep 1Kevin FeeleyCFO372 sh$31KSellJun 16Kevin FeeleyCFO3.7K sh$227KSellJun 16Katherine StuelandCEO10.5K sh$638KSellJun 9Katherine StuelandCEO3.6K sh$196KSellJun 9Kevin FeeleyCFO1.3K sh$68KBuyJun 5Casdin Capital, LlcDirector50.0K sh$2.6M
1–10 of 18
+ 23 other (16 exempts · 7 awards) in window

See when $WGS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 238-K — Item 5.07: Shareholder vote
AI summary

WGS filed an 8-K covering Item(s) 5.07. Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2026, GeneDx Holdings Corp., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders (the “Stockholders”) considered and voted on the matters listed below. The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2026. Ther. Investors should review the full filing for complete details.

3New insider — initial holdingsJun 163
AI summary

GARDNER MARK A filed an initial Form 3 as 10%+ owner of WGS, reporting no beneficial ownership of securities as of the event date. This is an administrative Section 16 filing required upon becoming a new 10%+ owner. No shares are currently held, indicating this is a disclosure of a newly appointed insider with no current equity position.

8-KOfficer or director changeJun 168-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

WGS filed an 8-K under Item 5.02 disclosing a personnel change: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The filing also covers Item(s) 7.01, 9.01. Personnel changes at the executive or board level are typically administrative but can signal strategic shifts depending on context.

SC 13D/AActivist amendmentMay 22SC 13D/A
SC 13D/AActivist amendmentMay 15SC 13D/A
SC 13D/AActivist amendmentMay 11SC 13D/A
+ 11 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) Stockdefenseworld.net·9d agoTempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovationgurufocus.com·18d agoGeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type Cbusinesswire.com·20d ago3 Promising Genomics Stocks in the Spotlight in 2026zacks.com·21d agoGeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoreebusinesswire.com·28d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$GRAL$NTRA$ILMN$TMO$DHR$GH
Voices on X · last 7 days

No standout posts about $WGS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport